March 11, 2019 – Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Trazimera (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab),1 for the treatment of human epidermal growth factor…Original Article
FDA Approves Trazimera (trastuzumab-qyyp), a Biosimilar to Herceptin
